NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The slide showing interim survival analysis among patients with recurrent GBM (>50% at 2 years), shared by Dr. Liau late last year, is really intriguing even though the number of patients is small.

Besides being very small, nobody knows what she is really saying as the slide does not match the trial.

The trial has DC and Poly on both arms. One arm is PD1 before and after surgery while the other has no PD1.

The slide has one arm with PD1 before surgery and one with PD1 after surgery.

I do not have the entire context of the slide, but it does not align with the trial. So who knows what it means?